Actively Recruiting
The Study of Efficacy and Safety of Dimephosphon® in Acute Ischemic Stroke
Led by Tatchempharmpreparaty, JSC · Updated on 2025-09-11
184
Participants Needed
6
Research Sites
33 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Dimephosphon® in acute ischemic stroke
CONDITIONS
Official Title
The Study of Efficacy and Safety of Dimephosphon® in Acute Ischemic Stroke
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Written informed consent obtained from patient or legal representative prior to participation
- Age between 35 and 80 years
- Neurological signs consistent with acute ischemic stroke with onset-to-treatment time between 24 and 72 hours
- Current hemispheric ischemic stroke verified by CT or MRI
- NIH Stroke Scale score between 5 and 15 at screening
- Ability to comply with all study procedures and restrictions
- Willingness and ability to use highly effective contraception as required by the study protocol
You will not qualify if you...
- Hemorrhagic stroke, hemorrhagic transformation of ischemic focus, or traumatic brain injuries
- Vertebrobasilar stroke or acute insufficiency in vertebrobasilar arteries
- Candidates for or prior recipients of reperfusion therapy before study participation
- Anatomical abnormalities of cerebral vessels such as arteriovenous malformations, cavernous malformations, aneurysms, or artery atresia
- Progression of stroke symptoms with NIHSS score increase of 4 points before randomization
- Carotid artery surgery less than 1 year before screening
- Stroke history less than 1 year before screening
- Myocardial infarction less than 6 months before screening
- Chronic renal failure stage 2-3 with creatinine clearance below 40 ml/min
- Pregnancy or breastfeeding
- Participation in another clinical trial within 28 days before enrollment
- Use of prohibited medications
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 6 locations
1
State Budgetary Healthcare Institution of the Leningrad Region "Vsevolozhsk Interdistrict Clinical Hospital
Vsevolozhsk, Leningradskaya Oblast', Russia, 188643
Actively Recruiting
2
State Budgetary Healthcare Institution "Research Institute - Regional Clinical Hospital No. 1 named after Professor S.V. Ochapovsky" of the Ministry of Health of the Krasnodar region
Krasnodar, Russia, 350086
Not Yet Recruiting
3
Federal State Autonomous Educational Institution of Higher Education "Peoples' Friendship University of Russia named after Patrice Lumumba"
Moscow, Russia, 117198
Actively Recruiting
4
The FSBI "Federal Center of Brain Research and Neurotechnologies" of the Federal Medical and Biological Agency
Moscow, Russia, 117513
Actively Recruiting
5
Saint Petersburg State Budgetary Healthcare Institution "City Hospital No. 40 of the Kurortny District"
Saint Petersburg, Russia, 197706
Actively Recruiting
6
State Budgetary Healthcare Institution "City Hospital No. 4 of Sochi" of the Ministry of Healthcare of the Krasnodar Region
Sochi, Russia, 354057
Actively Recruiting
Research Team
A
Alfiya Fakhrieva
CONTACT
A
Alyona Tirskaya
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here